Research graph
References from One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial. Local targets link to admitted publications; unresolved targets remain external evidence.
T‐cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)
10.1182/blood-2009-08-231217 · 2009 · External reference
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T‐cell acute lymphoblastic leukemia (T‐ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study
10.1182/blood-2008-10-184069 · 2009 · External reference
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
10.1182/blood-2006-05-018192 · 2007 · External reference
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T‐cell malignancies: a report from the Children's Oncology Group
10.1200/jco.2005.03.426 · 2005 · External reference
Phase I study of 506U78 administered on a consecutive 5‐day schedule in children and adults with refractory hematologic malignancies
10.1200/jco.2005.03.199 · 2005 · External reference
Nelarabine induces complete remissions in adults with relapsed or refractory T‐lineage acute lymphoblastic leukemia or lymphoblastic lymphoma; Cancer and Leukemia Group B study 19801
10.1182/blood-2006-11-056754 · 2007 · External reference
High single‐drug activity of nelarabine in relapsed T‐lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
10.1182/blood-2011-01-329441 · 2011 · External reference
Nelarabine can be safely incorporated into an intensive, multiagent chemotherapy regimen for the treatment of T‐cell acute lymphocytic leukemia (ALL) in children: a report of the Children's Oncology Group (COG) AALL00P2 protocol for T‐cell leukemia
10.1182/blood.v108.11.1864.1864 · 2006 · External reference
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T‐cell lymphoblastic leukaemia and lymphoma
10.1111/j.1365-2141.2010.08236.x · 2010 · External reference
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
10.1182/blood-2005-04-1623 · 2005 · External reference
Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta‐analysis
10.1001/jamaoncol.2017.0580 · 2017 · External reference
Early T‐cell precursor leukaemia: a subtype of very high‐risk acute lymphoblastic leukaemia
10.1016/s1470-2045(08)70314-0 · 2009 · External reference
Early T‐cell precursor acute lymphoblastic leukemia/lymphoma (ETP‐ALL/LBL) in adolescents and adults: a high‐risk subtype
10.1182/blood-2015-08-661702 · 2016 · External reference
Absence of biallelic TCR γ deletion predicts early treatment failure in pediatric T‐cell acute lymphoblastic leukemia
10.1200/jco.2010.28.3390 · 2010 · External reference
Immature MEF2C‐dysregulated T‐cell leukemia patients have an early T‐cell precursor acute lymphoblastic leukemia gene signature and typically have non‐rearranged T‐cell receptors
10.3324/haematol.2013.090233 · 2014 · External reference
The genomic basis of childhood T‐lineage acute lymphoblastic leukaemia
10.1038/s41586-024-07807-0 · 2024 · External reference
Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T‐cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial
10.3324/haematol.2017.185801 · 2018 · External reference
Toward a NOTCH1/FBXW7/RAS/PTEN–based oncogenetic risk classification of adult T‐cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study
10.1200/jco.2012.48.5292 · 2013 · External reference
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T‐cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial
10.1038/leu.2012.176 · 2013 · External reference
Impact of PTEN abnormalities on outcome in pediatric patients with T‐cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
10.1038/leu.2015.206 · 2016 · External reference
Prognostic value of oncogenetic mutations in pediatric T acute lymphoblastic leukemia: a comparison of UKALL2003 and FRALLE2000T protocols
10.1038/s41375-021-01334-x · 2022 · External reference
RASandTP53can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
10.1002/cam4.2757 · 2020 · External reference
Unresolved reference
2022 · External reference
In‐vivo T‐cell depleted reduced‐intensity conditioned allogeneic haematopoietic stem‐cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single‐arm evaluation of the UKALL14 trial
10.1016/s2352-3026(22)00036-9 · 2022 · External reference
IKZF1 alterations are not associated with outcome in 498 adults with B‐precursor ALL enrolled in the UKALL14 trial
10.1182/bloodadvances.2021004430 · 2021 · External reference
Sarek: A portable workflow for whole‐genome sequencing analysis of germline and somatic variants
10.12688/f1000research.16665.2 · 2020 · External reference
Fast and accurate short read alignment with Burrows‐Wheeler transform
2009 · External reference
The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data
10.1101/gr.107524.110 · 2010 · External reference
Maftools: efficient and comprehensive analysis of somatic variants in cancer
10.1101/gr.239244.118 · 2018 · External reference
Integrative genomics viewer
10.1038/nbt.1754 · 2011 · External reference
Pegylated‐asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
10.1038/leu.2016.219 · 2017 · External reference
Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T‐cell acute lymphoblastic leukemia
10.1200/jco.20.00256 · 2020 · External reference
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
10.1182/blood-2016-03-643544 · 2016 · External reference
Outcome for children and young people with E arly T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
10.1111/bjh.12882 · 2014 · External reference
Early response–based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study
10.1200/jco.2016.71.8585 · 2017 · External reference
Prognostic significance of ETP phenotype and minimal residual disease in T‐ALL: a Children's Oncology Group study
10.1182/blood.2023020678 · 2023 · External reference
Classification and risk stratification in T‐lineage acute lymphoblastic leukemia
10.1182/blood.2023022920 · 2025 · External reference
SAMHD1 protects cancer cells from various nucleoside‐based antimetabolites
10.1080/15384101.2017.1314407 · 2017 · External reference
SAMHD1 is a key regulator of the lineage‐specific response of acute lymphoblastic leukaemias to nelarabine
10.1038/s42003-020-1052-8 · 2020 · External reference
NGS‐based stratification refines the risk stratification in T‐ALL and identifies a very‐high‐risk subgroup of patients
10.1182/blood.2023023754 · 2024 · External reference
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study
10.1182/bloodadvances.2023011661 · 2024 · External reference
Improved outcome for children and young adults with T‐cell acute lymphoblastic leukaemia (ALL): results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
10.1182/blood.v112.11.908.908 · 2008 · External reference
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
10.1182/blood.2024024493 · 2024 · External reference
Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma
10.1158/2159-8290.cd-20-1465 · 2021 · External reference
